Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

boiron - paeonia officinalis 30k 1 % - pillules - 30k - paeonia officinalis 30k 1 %

Philippines - English - FDA (Food And Drug Administration)

eon pharmatek, inc.; distributor: eon pharmatek, inc. - calcitriol , calcium citrate , magnesium oxide , zinc oxide - capsule - 0.25mcg/425mg/40mg/20mg

United States - English - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - exenatide (unii: 9p1872d4ol) (exenatide - unii:9p1872d4ol) - exenatide 2 mg in 0.65 ml - bydureon is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus [see clinical studies (14)]. limitations of use : bydureon is contraindicated in patients with: limited data with exenatide, the active ingredient in bydureon, in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . based on animal reproduction studies, there may be risks to the fetus from exposure to bydureon during pregnancy. bydureon should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. animal reproduction studies identified increased adverse fetal and neonatal outcomes from exposure to exenatide extended-release during pregnancy, or from exposure to exenatide, during pregnancy and lactation, in associatio

United States - English - NLM (National Library of Medicine)

vanda pharmaceuticals inc. - tasimelteon (unii: shs4pu80d9) (tasimelteon - unii:shs4pu80d9) - tasimelteon 20 mg - - hetlioz capsules are indicated for the treatment of non-24 in adults. - hetlioz capsules are indicated for the treatment of nighttime sleep disturbances in sms in patients 16 years of age and older. - hetlioz lq oral suspension is indicated for the treatment of nighttime sleep disturbances in sms in pediatric patients 3 to 15 years of age. none. risk summary available postmarketing case reports with hetlioz use in pregnant women are not sufficient to evaluate drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in pregnant rats, no embryofetal developmental toxicity was observed at exposures of 50 mg/kg/day, or up to 24 times higher than the human exposure at the maximum recommended human dose (mrhd) (see data). the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2

United States - English - NLM (National Library of Medicine)

washington homeopathic products - paeonia - to relieve the symptoms of hemorrhoids. indications: paeonia   hemorrhoids if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - paeonia - to relieve the symptoms of hemorrhoids. indications:  paeonia   hemorrhoids if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

Israel - English - Ministry of Health

astrazeneca (israel) ltd - exenatide - powder and solvent for suspension for injection - exenatide 2 mg - exenatide - exenatide - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - enfuvirtide, quantity: 90 mg - diluent, not applicable - excipient ingredients: water for injections - fuzeon (enfuvirtide) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral experienced patients with treatment failure due to intolerance to previous antiretroviral agents or with evidence of hiv-1 replication despite ongoing therapy. evidence to support this indication is based on surrogate endpoints (change in viral load and cd4 count) in controlled studies following 48 weeks of treatment (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - enfuvirtide, quantity: 90 mg - injection, powder for - excipient ingredients: sodium carbonate; sodium hydroxide; hydrochloric acid; mannitol - fuzeon (enfuvirtide) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in antiretroviral experienced patients with treatment failure due to intolerance to previous antiretroviral agents or with evidence of hiv-1 replication despite ongoing therapy. evidence to support this indication is based on surrogate endpoints (change in viral load and cd4 count) in controlled studies following 48 weeks of treatment (see clinical trials)

Israel - English - Ministry of Health

astrazeneca (israel) ltd - exenatide - powder and solvent for suspension for injection - exenatide 2 mg - exenatide - bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control .